Amide derivatives of butyric acid for use in the treatment or prevention of sars-cov-2 infection
OwnerCarmine SPERAinventor
Life of this patent
Estimating the term…
Abstract
Methods for preventing or reducing SARS-CoV-2 entry in a subject's cells and for preventing or reducing an inflammatory cascade induced by a SARS-CoV-2 infection in a subject that involve administering to the subject of an effective amount of a composition including an amide derivative of butyric acid or a mixture of amide derivatives of butyric acid are provided. Preferably, the amide derivative of butyric acid is N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA).
Claims21
A method for preventing or reducing SARS-CoV-2 entry in a subject's cells, said method comprising administering to the subject of an effective amount of a composition comprising an amide derivative of butyric acid selected from the group consisting of N-(1-carbamoyl-2-phenyl-ethyl)butyramide (FBA), N-(1-butyroyl-carbamoyl-2-phenyl-ethyl)butyramide, 5-benzyl-2-propyl-1H-imidazol-4(5H)-one, N-(1-oxo-3-phenyl-1-(piperidin-1-yl)propan-2-yl)butyramide, N-(1-oxo-3-phenyl-1-(pyrrolidin-1-yl)propan-2-yl)butyramide, N-(1-(methylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(ethylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(propylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(butylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(pentylcarbamoyl)-2-phenylethyl)butyramide, N-(1-carbamoyl-2-phenylethyl)-N-methylbutyramide, N-(1-carbamoyl-2-phenylethyl)-N-ethylbutyramide, N-(1-carbamoyl-2-phenylethyl)-N-propylbutyramide, pharmaceutically acceptable salts, diastereoisomes and enantiomers thereof, or comprising any combination of the amide derivatives of butyric acid, pharmaceutically acceptable salts, diastereoisomes and enantiomers thereof.
(canceled)
(canceled)
(canceled)
A method for preventing or reducing an inflammatory cascade induced by a SARS-CoV-2 infection in a subject, said method comprising administering to the subject of an effective amount of a composition comprising an amide derivative of butyric acid selected from the group consisting of N-(1-carbamoyl-2-phenyl-ethyl)butyramide (FBA), N-(1-butyroyl-carbamoyl-2-phenyl-ethyl)butyramide, 5-benzyl-2-propyl-1H-imidazol-4(5H)-one, N-(1-oxo-3-phenyl-1-(piperidin-1-yl)propan-2-yl)butyramide, N-(1-oxo-3-phenyl-1-(pyrrolidin-1-yl)propan-2-yl)butyramide, N-(1-(methylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(ethylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(propylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(butylcarbamoyl)-2-phenylethyl)butyramide, N-(1-(pentylcarbamoyl)-2-phenylethyl)butyramide, N-(1-carbamoyl-2-phenylethyl)-N-methylbutyramide, N-(1-carbamoyl-2-phenylethyl)-N-ethylbutyramide, N-(1-carbamoyl-2-phenylethyl)-N-propylbutyramide, pharmaceutically acceptable salts, diastereoisomes and enantiomers thereof, or comprising any combination of the amide derivatives of butyric acid, pharmaceutically acceptable salts, diastereoisomes and enantiomers thereof.
Dependencies are inferred from the claim text.